Log In
Print
BCIQ
Print
Print this Print this
 

rituximab (BI 695500)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionRituximab biosimilar
Molecular Target CD20
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today